XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
G
G

GSK

News

Reuters - 1 week ago

Northwestern sues Moderna for patent infringement over 19 vaccines

Northwestern sues Moderna for patent infringement over COVID-19 vaccines By Blake Brittain Oct 16 (Reuters) - Moderna MRNA.O was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger
G
P
Reuters - 1 week ago

UK Stocks-Factors to watch on Oct. 16

UPDATE 1-UK Stocks-Factors to watch on Oct. 16 Adds news items Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening h igher on Wednesday, with futures FFIc1 u p 0 .4%. * ANTOFAGASTA: Antofagasta ANTO.L reported a 15% rise in third-quarter copper output compared to the second quarter, due to destocking of inventories at its Los Pelambres mine and better grades at its Centinela mine in Chile.
A
G
W
Reuters - 1 week ago

UK Stocks-Factors to watch on Oct 16

UK Stocks-Factors to watch on Oct 16 Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.09%. * GSK: British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia.
B
G
W
U
Reuters - 1 week ago

GSK sues Moderna for US patent infringement over COVID, RSV vaccines

UPDATE 2-GSK sues Moderna for US patent infringement over COVID, RSV vaccines Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna Adds information about RSV vaccine claims in paragraphs 1 and 6 By Blake Brittain Oct 15 (Reuters) - British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S.
G
N
P
Reuters - 1 week ago

GSK Says Both Anchor Trials Of Depemokimab Met Their Co-Primary Endpoints

BRIEF-GSK Says Both Anchor Trials Of Depemokimab Met Their Co-Primary Endpoints Oct 14 (Reuters) - GSK plc GSK.L : GSK PLC - POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB GSK PLC - PRIMARY ENDPOINTS MET WITH SIGNIFICANT REDUCTION IN NASAL POLYP SIZE GSK PLC - POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB GSK PLC - SIMILAR INCIDENCE AND SEVERI
G
Reuters - 2 weeks ago

UK stocks slip as some companies trade ex-dividend; GSK shines

UPDATE 1-UK stocks slip as some companies trade ex-dividend; GSK shines For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window GSK rises after settlement of 80,000 Zantac litigations Precious metal miners jump on gold surge FTSE 100 down 0.1%, FTSE 250 off 0.6% Updated at 1550 GMT By Shubham Batra and Khushi Singh Oct 10 (Reuters) - The UK's main stock indexes slipped on Thursday as some of the companies traded without the entitlement of their
A
E
G
K
T
N
T
U
Reuters - 2 weeks ago

Sanofi sale is critical health check for mega LBOs

BREAKINGVIEWS-Sanofi sale is critical health check for mega LBOs The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Oct 10 (Reuters Breakingviews) - Sanofi SASY.PA is about to deliver a critical health check to the buyout world. The $140 billion French pharmaceutical group is in talks with rival bidders Clayton Dubilier & Rice and PAI Partners to sell its consumer drugs unit for 15 billion euros, per Bloomberg reports.
G
G
S
Reuters - 2 weeks ago

Oil prices could reach $90/bbl if Middle East conflict hits supplies

LIVE MARKETS-Oil prices could reach $90/bbl if Middle East conflict hits supplies STOXX 600 down 0.2% Healthcare leads, tech lags GSK jumps on Zantac settlement Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com OIL PRICES COULD REACH $90/BBL IF MIDDLE EAST CONFLICT HITS SUPPLIES A supply disruption from escalating tensions in the Middle East could see oil pric
G
B
E
F
U
G
Reuters - 2 weeks ago

European shares mostly lower; markets await US CPI

LIVE MARKETS-European shares mostly lower; markets await US CPI STOXX 600 down 0.2% Healthcare leads, tech lags GSK jumps on Zantac settlement Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN SHARES MOSTLY LOWER; MARKETS AWAIT US CPI Major European bourses nudged lower on Thursday as markets awaited U.S.
G
B
E
F
U
G
Reuters - 2 weeks ago

GSK rises after settlement of 80,000 Zantac litigations

BUZZ-GSK rises after settlement of 80,000 Zantac litigations ** Shares of British drugmaker GSK GSK.L gains 5.4% to 1,536p - top gainer on FTSE 100 .FTSE index ** Shares on track for the best one-day pct gain since Dec. 2022 ** Settled about 80,000 or 93% of Zantac litigations for up to $2.2 bln ** Analysts had estimated costs as high as $3.5 bln *
G
U
Reuters - 2 weeks ago

GSK shares jump on $2.2 billion Zantac settlement

UPDATE 3-GSK shares jump on $2.2 billion Zantac settlement Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Rewrites paragraphs 1-3, adds investor comment in 4-5 By Maggie Fick and Yamini Kalia Oct 10 (Reuters) - GSK GSK.L shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S.
G
J
P
S
U
Reuters - 2 weeks ago

New York Times business news - Oct 10

PRESS DIGEST- New York Times business news - Oct 10 Oct 10 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - British drugmaker GSK GSK.L said it would pay up to $2.2 billion to settle most lawsuits filed against it in the U.S. that claimed a discontinued version of its heartburn drug Zantac caused cancer.
G
Reuters - 2 weeks ago

UK Stocks-Factors to watch on Oct 10

UPDATE 1-UK Stocks-Factors to watch on Oct 10 Adds new items, updates futures Oct 10 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday, with futures FFIc1 up 0.2%. * TRITAX EUROBOX: Brookfield Asset Management BAM.TO has agreed to buy Tritax EuroBox EBOX.L for 1.1 billion pounds ($1.44 billion), including debt, kicking off a possible takeover battle for the European logistics real estate firm.
G
H
K
T
W
T
Reuters - 2 weeks ago

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits Oct 10 (Reuters) - Shares of GSK GSK.L are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn drug Zantac caused cancer. The agreement, announced on Wednesday, resolved 80,000 or 93% of the pending cases against the company in the U.S.
G
J
Reuters - 2 weeks ago

British Business - Oct 10

PRESS DIGEST-British Business - Oct 10 Oct 10 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British paper and packaging firm Mondi MNDI.L has agreed to buy the German, Benelux and UK packaging assets of Schumacher Packaging for 634 million euros ($693.79 million) including debt, to expand in Western Europe.
G
M
Reuters - 2 weeks ago

UK Stocks-Factors to watch on Oct 10

UK Stocks-Factors to watch on Oct 10 Oct 10 - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.29%. * GSK: GSK GSK.L has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday. * METALS: Copper prices rose in London on Thursday, rebounding from a two-week low hit in the previous session, as traders and investors awaited a China b
G
K
T
W
T
Reuters - 2 weeks ago

Financial Times - Oct 10

PRESS DIGEST- Financial Times - Oct 10 Oct 10 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - HSBC targets senior bankers in cost-cutting plan - UK ministers fire starting gun on landmark worker rights reform - GSK reaches $2.2 bln Zantac settlement in US - Bernard Arnault partners with Red Bull to buy Paris FC in latest move into sport Overview - HSBC HSBA.L CEO Georges Elhedery plans
G
H
L
Reuters - 2 weeks ago

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln

UPDATE 2-GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing New throughout, adds detail on litigation, statements from plaintiffs and GSK By Brendan Pierson Oct 9 (Reuters) - GSK GSK.L has agreed to pay up to $2.2 billion to settle most lawsuits in U.S.
G
P
S
Reuters - 2 weeks ago

GSK reaches up to $2.2 billion settlement in Zantac US state court cases

GSK reaches up to $2.2 billion settlement in Zantac US state court cases Oct 9 (Reuters) - GSK GSK.L said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion. Reporting by Aatrayee Chatterjee in Bengaluru
G
Reuters - 2 weeks ago

GSK Says Company To Resolve 93% Of U.S. Zantac Cases For Up To $2.2 Billion

BRIEF-GSK Says Company To Resolve 93% Of U.S. Zantac Cases For Up To $2.2 Billion Oct 9 (Reuters) - GSK plc GSK.L : GSK PLC - ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS GSK PLC - TO RESOLVE 93% OF U.S. ZANTAC CASES FOR UP TO $2.2 BILLION GSK PLC - SETTLES QUI TAM COMPLAINT FOR $70 MILLION GSK PLC - TO RECOGNISE £1.8 BILLION CHARGE IN Q3 RESULTS FO
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.